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Purpose: Acinetobacter baumannii (A. baumannii) has emerged as a major cause 
of nosocomial pneumonia and sepsis in seriously ill patients. Multidrug-resistant 
A. baumannii (MDRAB) is increasing in frequency, and the management of it’s 
infections is consequently difficult. Therefore, tigecycline is considered to be the 
drug of choice for MDRAB treatment. The aim of our study was to evaluate the 
microbiological eradication and clinical effectiveness of tigecycline against 
MDRAB in seriously ill patients, including patients with ventilator-associated 
pneumonia (VAP). Materials and Methods: We conducted a retrospective study 
including patients with A. baumannii infections who were treated with tigecycline 
between April 1, 2009 and March 31, 2010. We treated 27 patients with tigecy-
cline for MDRAB infections. Results: The mean age of patients was 66.2 years, 
and 20 (74.1%) patients were male. The median length of stay at hospital was 74.6 
days. MDRAB was eradicated from the site of infection in 23 cases (85.2%), how-
ever, only 17 cases (63.0%) showed positive clinical responses. Overall, an in-hos-
pital mortality rate of 51.9% was observed, and 4 cases of death were attributable 
to sepsis. The combination therapy showed better clinical and microbial success 
rates than the monotherapy without significant difference. Conclusion: We ob-
served the relatively low clinical success rate although the microbial eradication 
rate was high, probably due to superinfections in VAP and bacteremia. We suggest 
that clinicians should limit tigecycline monotherapy for MDRAB infection in criti-
cally ill patients, until large controlled clinical trials should be conducted.
Key Words:   Acinetobacter baumannii, bacteremia, multidrug resistance, tigecy-
cline, ventilator-associated pneumonia
INTRODUCTION
Acinetobacter baumannii (A. baumannii) has emerged as a major cause of nosoco-
mial pneumonia [particularly ventilator-associated pneumonia (VAP)], blood-
stream infection and sepsis in immunocompromised and seriously ill patients.1,2 
Mortality of critically ill patients with A. baumannii infections is high.3-7 Further-
more, multidrug-resistant A. baumannii (MDRAB) is increasing in frequency and 
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ing organisms other than MDRAB. For polymicrobial in-
fections, patients were included only if tigecycline treat-
ment was determined by the presence of MDRAB.  
Data recorded for each patient included the following: age, 
gender, associated co-morbidities and previous antimicrobial 
regimens, site of infection, major reason for hospital admis-
sion and length of intensive care unit stay. Disease severity 
was assessed by Acute Physiology and Chronic Health Eval-
uation II (APACHE II) scores upon ICU admission and on 
day 1 of tigecycline therapy.  
Definitions  
MDRAB was defined if A. baumannii isolate was resistant 
to representative antibiotics of at least three different classes 
of antimicrobial agents such as aminoglycosides, anti-pseu-
domonal penicillins, carbapenems, cephalosporins, quino-
lones, colistin, ampicillin/sulbactam and/or tetracyclines.20,21 
We defined MDRAB infection as clinical findings of pneu-
monia such as fever, changing patterns of sputum or signs 
of SIRS and identification of MDRAB in the respiratory or 
blood samples with suspected pathogen by attending physi-
cians.22-24 We defined management as tigecycline adminis-
tration and followed up the patients until tigecycline admin-
istration was stopped, without regard to clinical outcome of 
success or failure.
Clinical outcomes were evaluated by attending physicians 
using data from patient files in cooperation with the investi-
gators. The decisions to begin and end the tigecycline treat-
ment were made by the attending physician. The duration 
of tigecycline treatment was decided according to its clini-
cal responses.  
Clinical response at the end of treatment was defined as 
success (complete or partial resolution of signs/symptoms) 
or failure (no improvement or deterioration of signs/symp-
toms of infection). Microbiological response was defined as 
success (eradication/sterile culture results during or after the 
course of antibiotic therapy) or failure (continuously posi-
tive culture results or the development of a superinfection 
due to treatment). In polymicrobial infections, microbiolog-
ical response was considered positive if MDRAB was erad-
icated from the primary site of infection.  
VAP, bloodstream infections (BSI), and sepsis were de-
fined according to American Thoracic Society/Centers for 
Disease Control and Prevention clinical diagnostic criteria.25
All-cause mortality during 14 days from the start of tige-
cycline treatment was recorded. Death caused by primary 
infection was defined as death occurring without resolution 
it’s management can consequently be difficult.4,8-10 Carbap-
enems have become the therapy of choice for serious A. 
baumannii infections, however, carbapenem-resistant or-
ganisms are also becoming more common.11-14 
Many MDRAB strains remain susceptible to tigecycline 
in vitro.15 However, reports of MDRAB are increasing, as 
confirmed by a European study group16 and an American 
study group17 that showed 51-67% resistance to quinolones 
and 40-63% resistance to third generation cephalosporins. 
Moreover, carbapenem resistance has increased to 12-47%. 
Resistance to colistin is also reported to be up to 22%, and 
the nephrotoxicity of colistin limits its usage in many seri-
ously ill patients with renal failure.16,17 Therefore, when these 
drugs are not effective in MDRAB infections, tigecycline is 
considered as the drug of choice.  
Even though some observational studies have shown that 
VAP caused by MDRAB was an important indication for 
the use of tigecycline,18-21 the role of tigecycline in VAP con-
trol is still uncertain. Extended clinical experience in criti-
cally ill patients with MDRAB infections is poor, and most 
of the available publications are retrospective with small 
numbers of patients or with assorted co-administered anti-
biotics. Therefore, experience with tigecycline in the treat-
ment of critically ill patients, including patients with VAP, 
is lacking.  
The aim of this retrospective study was to report our ex-
perience of the microbiological and clinical effectiveness of 
tigecycline against MDRAB infections in seriously ill pa-
tients, including those with VAP.  
MATERIALS AND METHODS
　　　
Study design and data collection  
A retrospective study was conducted at Gangnam Sever-
ance Hospital, Seoul, Korea. This study was approved by 
the Institutional Review Board, Gangnam Severance Hos-
pital, Yonsei University College of Medicine (IRB Num-
ber: 3-2011-0017). 
The enrolled patients were intensive care unit (ICU) ad-
mitted adults (age ≥18 years) with MDRAB infections who 
were treated with tigecycline between April 1, 2009 and 
March 31, 2010. Tigecycline was administered intravenous-
ly at a dose of 50 mg every 12 hours after a loading dose of 
100 mg. Exclusion criteria were as follows: age <18 years, 
duration of tigecycline treatment <5 days, administration of 
tigecycline as empirical treatment or for infections involv-
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Drug susceptibility test revealed resistance to imipenem 
and meropenem in 85% (22/27) and 81% (23/27) of cases, re-
spectively. Resistance to colistin was observed in 22.2% 
(6/27, 5 of resistance and 1 of intermediate) of cases (Table 3). 
Twenty-six patients had been treated with antibiotics pri-
or to the current hospitalization, and 18 of these patients 
(69.0%) were treated with more than two antibiotics. Piper-
acillin-tazobactam, respiratory quinolones, carbapenems, 
and third/fourth generation cephalosporins were the most 
frequently used prior antibiotics (37.0%, 33.3%, 25.9% and 
25.9%, respectively) (data not shown). The average length 
of treatment was 14.5±7.5 days.  
Tigecycline was administered in 17 patients (54.4%) as 
monotherapy and in combination with other antibiotics in 
10 patients. In combination therapy group, 2 cases adminis-
tered another antibiotics or antifungal agents for other patho-
gens prior to MDRAB identification. Metronidazole was 
the most common concomitant antibiotic (30.0%). It was 
not for MDRAB infection, but overlap maintenance for pri-
or clinically suspected anaerobic infection. Three patients 
in the combination therapy group were treated with anti-
fungal agents such as fluconazole and/or amphotericin B.  
There were no significant differences in the APACHE II 
scores at ICU admission between the monotherapy group 
and the combination therapy group (27.0±8.2 vs. 26.5±7.3); 
however the APACHE II scores on day 1 of treatment (23.4± 
5.5 vs. 29.6±4.0) and the duration of treatment (11.5±5.3 vs. 
19.5±8.2, days) were significantly different between the 
groups, suggesting that clinicians tend to choose combination 
therapy for clinically deteriorated patients (Table 1 and 2).  
Median duration between ICU admission and beginning 
of treatment was 33.8±28.6 days, and there was no statisti-
cal difference between monotherapy group and combina-
tion group (37.1±33.7 vs. 27.9±16.0 days, p=0.453) (data 
not shown). Some patients were admitted to ICU for vari-
ous reasons and infected with MDRAB during the ICU 
stay. Therefore, the duration between ICU admission and 
the beginning of tigecycline treatment for MDRAB infec-
tion did not show clinical significance.
Treatment outcomes  
In 23 cases (85.2%), MDRAB was eradicated from the site 
of infection, however, only 17 cases (63.0%) showed posi-
tive clinical response. Four patients died within 14 days of 
initiating treatment, representing a crude mortality rate of 
14.8%. One of these deaths was attributable to sepsis. An 
overall in-hospital mortality rate of 51.9% was observed, 
of signs and symptoms of infection and with no other cause 
identified. 
Nephrotoxicity was defined as an increase in serum cre-
atinine level of more than 50% above baseline (recorded on 
the first day of tigecycline treatment) at a value above the 
upper normal limit (>1.3 mg/dL). Underlying chronic renal 
failure was defined by a baseline creatinine clearance rate 
of less than 60 mL/min/1.73 m2.  
Statistical analysis  
Data were analyzed with SPSS version 18.0 statistical soft-
ware (SPSS, Chicago, IL, USA). All tests were two-sided. 
Categorical variables were compared by Fisher’s exact test 
and Pearson’s chi-square test as appropriate. Continuous 
variables were compared with Student’s t-test. A p-value 
≤0.05 was considered statistically significant.
 
RESULTS
 
Patient characteristics  
A total of 27 patients received tigecycline for MDRAB in-
fections between April 1, 2009 and March 31, 2010. All pa-
tients were treated with the standard regimen of a 100 mg 
loading dose followed by 50 mg intravenous tigecycline 
every 12 hours. Tigecycline administration was started in 
ICU, but some patients were transferred to general ward 
during management while clinically improved. Patient and 
pathogen characteristics are recorded in Table 1. The mean 
patient age was 66.2±10.8 years (44-83 years), and 20 
(74.1%) patients were male. The median APACHE II score 
upon ICU admission was 26.8±7.7 and 25.7±5.8 on day 1 
of tigecycline treatment. The median length of stay was 
74.6 days (range, 11-135) (Table 2).  
Tigecycline was considered to be the drug of choice for 
MDRAB infection because 5 patients showed colistin-re-
sistant MDRAB infection and 7 patients showed renal fail-
ure (eGFR <60 mL/min/BSA). Fifteen patients could not 
be treated with colistin due to the instability in stock of the 
drug in Korea at the time (data not shown).  
Four patients were treated with tigecycline for MDRAB 
as a single pathogen and 23 patients were treated for poly-
microbial infections. Methicillin-resistant coagulase-nega-
tive staphylococci (33.3%, 9/27) were the most common 
co-infected organisms, followed by Pseudomonas aerugi-
nosa (29.6%, 8/27) and methicillin-resistant Staphylococ-
cus aureus (MRSA) (22.2%, 6/27) (Table 1 and 2).  
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infection. In BSI, MDRAB was isolated from blood and 
sputum in all patients. Five of eight patients received mono-
therapy and others received combination therapy including 
tigecycline. The overall successful clinical response rate 
was 62.5%, and the microbial response rate was 87.5%. 
Two patients with clinical failure died due to superinfection 
(Table 5).  
DISCUSSION
Tigecycline has been approved for the treatment of compli-
cated intra-abdominal infections, complicated skin and soft 
tissue infections, and community-acquired bacterial pneu-
monia.26 However, the role of tigecycline in VAP is uncer-
tain and it has been considered an optional treatment for 
and death in four cases was attributable to sepsis (Table 4).  
Subanalysis by treatment group and infection  
The combination therapy group showed better clinical and 
microbial success rates without statistical significance. For 
14-day mortality and in-hospital mortality, there were no 
significant differences between the monotherapy and com-
bination therapy groups. Clinical and microbial success rate 
were not affected by infection type (Table 4).
In respiratory infections, 4 of 19 patients were treated for 
community-acquired pneumonia and others were treated 
for VAP. Twelve of 19 patients received monotherapy with 
tigecycline and others received combination therapy in-
cluding tigecycline. Overall, the successful clinical re-
sponse rate was 63.2%, and the microbial response rate was 
84.2%. Two patients with clinical failure died due to super-
Table 2. Characteristics of Patients Treated with Tigecycline  
Variable
Treatment group
p value
Total (n=27) Monotherapy (n=17) Combination (n=10)
Age (yrs, ±SD)   66.2±10.8   67.5±11.9   65.4±10.3 0.635
Sex (M/F) 20/7 14/3 6/4 0.201
APACHE II score (±SD)
    ICU admission 26.8±7.7 27.0±8.2 26.5±7.3 0.875
    Day 1 of treatment 25.7±5.8 23.4±5.5 29.6±4.0 0.004
Duration of treatment (days, ±SD) 14.5±7.5 11.5±5.3 19.5±8.2 0.005
Total length of stay (days, ±SD)   74.6±34.5   68.7±36.4   84.8±29.9 0.248
Reason of hospitalization 27 17 10 0.714
    Renal insufficiency   1   0   1
    Heart/vascular disease   5   3   2
    Malignancy   3   2   1
    Chronic respiratory disease   2   2   0
    Neurologic disease   4   3   1
    Microbial infection   4   3   1
    Orthopedics or minor surgery   3   1   2
    Gastroenteologic problem   5   3   2
Type of infection 0.974
    Respiratory infection 19 12   7
    Bloodstream infection   8   5   3
Pathogens 
    Acinetobacter baumannii 27 17 10
    Klebsiella pneumoniae   5   3   2 0.239
    Enterobacter cloacae   5   4   1 0.382
    MRSA   6   4   2 0.831
    MRCNS   9   8   1 0.049
    Pseudomonas aeruginosa   8   5   3 0.974
    Stenotrophomonas maltophilia   3   2   1 0.888
    EGNB   3   2   1 0.888
    Fungus   1   0   1 0.184
ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus; MRCNS, methicillin-resistant coagulase-negative Staphylococci.; EGNB, en-
teric gram-negative bacillus; SD, standard variation; M, male; F, female; APACHE II score, Acute Physiology and Chronic Health Evaluation II score.
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Table 3. Clinical and Microbiological Outcomes of Patients Treated with Tigecycline
Patient 
no.
Age Sex
Drug susceptibility
Co-administered 
antibiotics
Microbial 
response
Clinical 
response
14 day 
mortality
Hospital 
mortality
Death at-
tributable 
to sepsisAMK CIP GEN IMP MEP CEF TZB COL
  1 54 1 R R R S S R R R Combination Successful Successful No Yes No
  2 68 1 R R R R R R R R Monotherapy Successful Successful No No No
  3 61 2 R R R R R R R R Combination Successful Successful No No No
  4 77 1 R R R R R R R R Monotherapy Successful Successful No No No
  5 83 1 R R R R R R R S Combination Successful Failure No Yes Yes
  6 70 1 I R R R R R R R Combination Successful Failure No No No
  7 66 1 I R R R R R R S Monotherapy Successful Successful Yes Yes No
  8 71 2 R R R R R R R S Combination Successful Successful No Yes No
  9 70 1 S R S R R R R I Monotherapy Successful Successful Yes Yes No
10 68 1 R R R R R R R S Monotherapy Failure Failure No Yes No
11 83 1 R R R R R R R S Monotherapy Failure Failure No Yes Yes
12 78 1 S R R R R R R S Combination Successful Successful No No No
13 72 1 R R R S S I R S Monotherapy Successful Successful No No No
14 72 1 R R R R R R R S Monotherapy Successful Successful No No No
15 68 1 R R R R R R R S Monotherapy Successful Successful No No No
16 44 2 R R R R R R R S Monotherapy Failure Successful No No No
17 48 1 R R R S S R R S Monotherapy Successful Failure No Yes No
18 56 1 R R R R R R R S Monotherapy Successful Failure Yes Yes Yes
19 76 1 R R R S S R R S Monotherapy Successful Successful No No No
20 72 1 R R R R R R R S Combination Successful Failure Yes Yes No
21 54 2 R R R R R R R S Monotherapy Successful Successful No No No
22 61 1 R R R R R R R S Monotherapy Successful Failure No Yes Yes
23 62 1 R R R R R R R S Combination Successful Successful No Yes No
24 67 1 R R R S R I R S Monotherapy Successful Failure No No No
25 62 2 R R R R R R R S Monotherapy Failure Failure No Yes No
26 79 2 R R R R R R R S Combination Successful Successful No Yes No
27 45 2 R R R R R R I S Combination Successful Successful No No No
no., number; AMK, amikacin; CIP, ciprofloxacin; GEN, gentamicin; IMP, imipenem; MEP, meropenem; CEF, cefperazone; TZB, tazolactam/sulbactam; COL, 
colistin; R, resistance; I, intermediate; S, sensitive.
Table 4. Clinical Outcome and Mortality in Patient Treated with Tigecycline 
Variable
Total
n=27
Treatment group Infection type
Monotherapy
n=17
Combination 
therapy
n=10
p value
Respiratory 
infection
n=19
Bloodstream 
infection
n=8
p value
Previous antibiotics use, n 26 16 10 0.434 18   8 0.508
Previous carbapenem use, n   6   4   2 0.711   4   2 0.373
APACHE II (on ICU)* 26.8±7.7 27.0±8.2 26.5±7.3 0.875 27.6±7.2 25.0±9.0 0.439
APACHE II (on treatment)† 25.7±5.8 23.4±5.5 29.6±4.0 0.004 25.4±4.7 26.4±8.2 0.689
Clinical success, n (%) 17 (63.0) 10 (58.8)   7 (70.0) 0.561 12 (63.2) 5 (62.5) 0.974
Microbial success, n (%) 23 (85.2) 13 (76.5)   10 (100.0) 0.097 16 (84.2) 7 (87.5) 0.826
14 days mortality
    Attributable, n (%) 1 (3.7) 1 (5.9) 0 (0.0) 0.260 0 (0.0) 1 (12.5) 0.080
    Crude, n (%)   4 (14.8)   3 (17.6)   1 (10.0) 0.589 1 (5.3) 3 (37.5) 0.031
In hospital mortality
    Attributable, n (%)   4 (14.8)   3 (17.6)   1 (10.0) 0.711   2 (10.5) 2 (75.0) 0.064
    Crude, n (%) 14 (51.9)   8 (47.1)   6 (60.0) 0.516   7 (36.8) 7 (87.5) 0.033
n, number of patient; ICU, intensive-care unit; APACHE II score, Acute Physiology and Chronic Health Evaluation II score.
*On ICU: APACHE II score on 1st day of intensive care unit admission.
†On treatment: APACHE II score on 1st day of treatment with tigecycline.
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tion between clinical and microbiological outcomes increas-
es the debate regarding the inherent pathogenicity of A. 
baumannii.  
In respiratory infection, the clinical success rate was only 
63.2% with or without concomitant antibiotics (58.3% vs. 
71.4%), despite the fact that 84.2% showed microbial erad-
ication. Interestingly, in the BSI group the microbial eradi-
cation rate was 87.5% and the clinical success rate was 62.5% 
regardless of concomitant antibiotic treatment (60.0% vs. 
66.7%). We, therefore, hypothesize that tigecycline mono-
therapy was ineffective in several patients because most 
clinical failures were due to superinfection and there was a 
high Pseudomonas aeruginosa infection rate (29.6%). Al-
though multidrug resistant Pseudomonas aeruginosa was 
expected to be the most important and common pathogen 
in superinfections, we found that patients with superinfec-
tions tended to have lower previous or concomitant use of 
carbapenems and colistin. In addition, probable pharmacoki-
netic concerns might be related to the failure to improve in-
fections caused by sensitive microorganisms. Acquired re-
sistance to tigecycline and superinfections, due to 
intrinsically resistant pathogens to tigecycline, supports the 
possible benefits from combination therapy, as hypothe-
sized in large prospective and randomized studies.30 Mean-
while, selection of patients to receive tigecycline remains 
important.  
Above all, most of the respiratory infections (15/19) and 
BSI (7/8) represented hospital acquired pneumonia includ-
ing VAP, and we cannot at present affirm the efficacy of ti-
VAP caused by MDR organisms, except for Pseudomonas 
aeruginosa.  
Accumulated evidence has identified that tigecycline has 
considerable microbiological activity against MDRAB, in-
cluding carbapenem-resistant Acinetobacter spp. Neverthe-
less, many studies have revealed that the activity of tigecy-
cline is not optimal, suggesting that the use of tigecycline 
may not comprise a definitive solution of the growing prob-
lem of MDRAB. Nonetheless, the utility of tigecycline should 
not be disregarded because other antimicrobial agents, ex-
cept polymyxins, are not reliably active against carbapen-
em-resistant A. baumannii isolates.27 Recently, the Food 
and Drug Administration (FDA) determined that tigecy-
cline resulted in increased mortality risk, especially in hos-
pital-acquired pneumonia, compared with other antibiotics. 
We studied only tigecycline-treated patients infected with 
MDRAB, but not patients with VAP in general.  
We examined the microbiological activity and clinical ef-
fectiveness of tigecycline against MDRAB infections in 31 
seriously ill patients, including patients with VAP, and ob-
served a weak correlation between microbiological clear-
ance and clinical outcome. Overall, only 63.0% had positive 
clinical outcomes, whereas 85.2% had microbial eradica-
tion. A recent systematic review27 found an overall response 
rate of 76% to tigecycline for a wide range of MDRAB in-
fections. Several studies on the treatment of VAP have been 
reported; the proportion of global clinical success is 69-
88%28-30 and microbiological eradication is 80%28 with or 
without concomitant antibiotic therapy. The lack of correla-
Table 5. Subanalysis of Clinical Outcome and Mortality in Patient according to Infection Type
Respiratory infection Bloodstream infection
Monotherapy
n=12
Combination 
therapy
n=7
Total
n=19
p value
Monotherapy
n=5
Combination 
therapy
n=3
Total
n=8
p value
Previous antibiotics use, n 11 7 18 0.433 5 3 8 1.000
Previous carbapenem use, n   3 1   4 0.581 1 1 2 0.187
APACHE II (on ICU)* 27.3±7.5 28.0±7.4 27.6±7.2 0.852   26.2±10.7 23.0±7.0 25.0±9.0 0.664
APACHE II (on treatment)† 23.4±3.7 28.7±4.5 25.4±4.7 0.013 23.2±9.1 31.7±1.5 26.4±8.2 0.172
Clinical success, n (%)   7 (58.3)   5 (71.4) 12 (63.2) 0.568 3 (60.0)   2 (66.7) 5 (62.5) 0.850
Microbial success, n (%)   9 (75.0)     7 (100.0) 16 (84.2) 0.149 4 (80.0)     3 (100.0) 7 (87.5) 0.408
14 days mortality
    Attributable, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 1.000 1 (20.0) 0 (0.0) 1 (12.5) 0.206
    Crude, n (%) 0 (0.0)   1 (14.3) 1 (5.3) 0.179 3 (60.0) 0 (0.0) 3 (37.5) 0.090
In hospital mortality
    Attributable, n (%)   2 (16.7) 0 (0.0)   2 (10.5) 0.891 1 (40.0)   1 (66.7) 2 (75.0) 0.465
    Crude, n (%)   4 (33.3)   3 (42.8)   7 (36.8) 0.678 4 (80.0)     3 (100.0) 7 (87.5) 0.408
n, number of patient; ICU, intensive-care unit; APACHE II score, Acute Physiology and Chronic Health Evaluation II score.
*On ICU: APACHE II score on 1st day of intensive care unit admission.
†On treatment: APACHE II score on 1st day of treatment with tigecycline.
Jung Ar Shin, et al.
Yonsei Med J   http://www.eymj.org   Volume 53   Number 5   September 2012982
activity of tigecycline may be evidenced by the relatively 
long post-antibiotic effect of up to 3 hours against A. bau-
mannii, even though pharmacokinetic and pharmacody-
namic data indicate that blood concentrations are subopti-
mal for maximal antibacterial activity.31
There were no differences in laboratory findings includ-
ing GOT/GPT, total bilirubin, renal function, hemoglobin, 
or platelet count between the monotherapy group and the 
combination therapy group (Supplementary Table 1). There 
were also no differences in symptoms such as gastrointesti-
nal problems including pseudomembraneous colitis and 
gecycline for VAP. Nevertheless, randomized controlled tri-
als should provide more concrete evidence. Randomized 
phase III trial to compare tigecycline and imipenem/cilas-
tatin for nosocomial pneumonia25 found that clinical cure 
rates are poorer for tigecycline than with imipenem/cilas-
tatin in the subset of VAP patients, therefore, tigecycline 
has not been approved for the treatment of VAP, and clini-
cians have considered tigecycline to be a useful option for 
the treatment of patients with VAP based on its good in vitro 
activity and a pharmacokinetic profile with high intrapulmo-
nary concentrations.17,20 In fact, the excellent antimicrobial 
Supplementary Table 1. Laboratory Findings before and after Treatment with Tigecycline  
Variable 
Treatment group
p valueTotal 
(n=27)
Monotherapy 
(n=17)
Combination therapy 
(n=10)
Before treatment with tigecycline 
    White blood count (/mm3) 14615.9±7292.3 12648.8±5630.2 17960.0±8805.4
    Neutrophil count (%)   79.5±19.0   78.9±14.8   80.5±25.6
    Hemoglobin (g/dL) 10.0±1.6   9.9±2.0 10.1±1.0
    Platelet count (/mm3)   203.4±118.3   207.8±121.1   196.0±119.6
    C-reactive protein (mg/L) 124.5±93.0 101.5±82.9   163.5±100.2
    Creatinine (mg/dL)   1.5±1.1   1.1±0.6   2.0±1.5
    Calculated GFR (mL/min/1.73m3)   75.6±43.5   86.0±38.0   58.1±48.5
    GOT (IU/L)   54.9±56.7   67.4±68.1   33.8±16.5
    GPT (IU/L)   39.9±29.7   41.3±26.5   37.6±35.9
    Total bilirubin (mg/dL)   1.7±3.4   1.0±1.3   3.0±5.2
After treatment with tigecycline 
    White blood count (/mm3) 12439.3±5915.1 12634.7±4918.6 12107.0±7607.6
    Neutrophil count (%)   77.6±12.9   78.3±11.2   76.5±15.9
    Hemoglobin (g/dL)   9.9±1.6 10.0±1.7   9.7±1.5
    Platelet count (/mm3)   158.8±136.7   167.6±125.3   144.0±160.3
    C-reactive protein (mg/L)   85.3±83.6   84.1±98.6   87.4±53.7
    Creatinine (mg/dL)   1.3±1.0   1.1±0.5   1.6±1.6
    Calculated GFR (mL/min/1.73m3)   83.7±40.6   86.2±39.4   79.4±44.3
    GOT (IU/L)     285.9±1276.9     433.9±1608.2   34.4±26.3
    GPT (IU/L)     65.6±191.2     90.4±239.6   23.5±19.0
    Total bilirubin (mg/dL)   2.9±4.8   1.9±3.5   4.7±6.3
Laboratory difference between before and after tigecycline therapy
    ∆ White blood count (/mm3)  -2176.7±8902.1      -14.1±6823.1    -5853.0±11060.0 0.101
    ∆ Neutrophil count (%)    -1.9±18.8    -0.6±11.8    -4.0±27.6 0.663
    ∆ Hemoglobin (g/dL)   0.1±1.8  -0.1±1.9   0.4±1.5 0.473
    ∆ Platelet count (103/mm3)     44.6±109.8     40.2±105.9     52.0±121.7 0.794
    ∆ Creatinine (mg/dL)  -0.2±0.7  -0.0±0.5  -0.5±1.0 0.136
    ∆ Calculated GFR (mL/min/1.73m3)    -8.0±34.1    -0.2±28.2  -21.3±40.5 0.123
    ∆ GOT (IU/L)     25.7±186.4     49.1±232.2  -14.2±41.3 0.469
    ∆ GPT (IU/L)   0.2±0.4   0.2±0.5   0.1±0.3 0.405
    ∆ Total bilirubin (mg/dL)   1.4±3.8   1.1±3.2   1.7±4.7 0.694
    ∆ White blood count (/mm3)  -2176.7±8902.1      -14.1±6823.1   -5853.0±11060.0 0.101
    ∆ Neutrophil count (%)    -1.9±18.8    -0.6±11.8   -4.0±27.6 0.663
GFR, glomerular filtration rate; GOT, glutamyl oxloacetic transaminase; GPT, glutamyl pyruvic transaminase.
∆: laboratory difference between before tigecycline therapy and  after tigecycline therapy. 
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skin rashes (data not shown). We, therefore, suggest that 
concomitant antibiotic use may not significantly increase 
drug toxicity. In our study, newly onset nephrotoxicity in 
patients with normal renal function or renal function de-
cline in patients with renal insufficiency was not observed 
(patient No. 1, 2, 3, 5, 7, 8, 9, 10, 11, 20, 26). Considering 
the 10% incidence of nephrotoxicity of colistin, this result 
suggests that tigecycline is an important option for patients 
with chronic renal failure.32
Our study has several limitations. First, our study em-
ployed a retrospective design and small number of patients 
at a single tertiary hospital, therefore, generalization to other 
clinical setting is limited. Second, there is a lack of pharma-
cokinetic and pharmacodynamic data, as we were unable to 
measure serum and intrapulmonary levels of tigecycline. 
In conclusion, we examined the clinical and microbial ef-
ficacy of tigecycline for MDRAB infection including the 
isolates that were resistant to carbapenem and/or colistin, 
and observed a relatively low clinical success rate although 
the microbial eradication rate was high, probably due to su-
perinfections in VAP and bacteremia. Although there was no 
significant difference between monotherapy and combina-
tion therapy groups, the combination therapy group showed 
better clinical and microbial success rates. We attribute the 
benefits from combination therapy to acquired resistance to 
tigecycline and superinfections with intrinsically resistant 
pathogens to tigecycline. Regarding the lack of data on tige-
cycline in the treatment of critically ill patients with MDRAB 
infection, we suggest that clinicians should limit tigecycline 
monotherapy for MDRAB infection to critically ill patients 
and consider the combination with anti-pseudomonal agent, 
while making reference to drug susceptibility test, until 
large controlled clinical trials should be conducted.  
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